NZ726636A - Novel compounds and compositions for targeting cancer stem cells - Google Patents
Novel compounds and compositions for targeting cancer stem cellsInfo
- Publication number
- NZ726636A NZ726636A NZ726636A NZ72663611A NZ726636A NZ 726636 A NZ726636 A NZ 726636A NZ 726636 A NZ726636 A NZ 726636A NZ 72663611 A NZ72663611 A NZ 72663611A NZ 726636 A NZ726636 A NZ 726636A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- stem cells
- novel compounds
- cancer stem
- subject
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- DPHUWDIXHNQOSY-UHFFFAOYSA-N napabucasin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 229950011456 napabucasin Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is the use of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione (napabucasin) for treatment of cancer in a subject in need thereof, wherein the medicament is formulated for administration to the subject at a total daily dose in a range of from about 20 mg to about 2000 mg. Also disclosed is treatment where napabucasin is administered at a dose sufficient to achieve a blood concentration of the compound in the subject of at least 1.0 μΜ or above for at least two hours, wherein the blood concentration of the compound in the subject is substantially cleared within at most 24 hours.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US32581410P | 2010-04-19 | 2010-04-19 | |
| NZ712826A NZ712826A (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ726636A true NZ726636A (en) | 2017-01-27 |
Family
ID=57835823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ726636A NZ726636A (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ726636A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109988157A (en) * | 2018-01-03 | 2019-07-09 | 四川大学 | New small molecule compound, preparation method and the purposes in terms of preparing the mycobacterias drug such as overriding resistance mycobacterium tuberculosis |
-
2011
- 2011-03-21 NZ NZ726636A patent/NZ726636A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109988157A (en) * | 2018-01-03 | 2019-07-09 | 四川大学 | New small molecule compound, preparation method and the purposes in terms of preparing the mycobacterias drug such as overriding resistance mycobacterium tuberculosis |
| CN109988157B (en) * | 2018-01-03 | 2022-12-27 | 四川大学 | Novel small molecular compound, preparation method and application in preparation of drug-resistant mycobacterium tuberculosis and other mycobacteria drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| WO2009039397A3 (en) | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| IL176707A0 (en) | New compounds, methods for their preparation and use thereof | |
| NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| MX2009006764A (en) | Bicyclic pyrimidinones and uses thereof. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ712826A (en) | Novel compounds and compositions for targeting cancer stem cells | |
| MX344476B (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations. | |
| MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| MX2011009709A (en) | Compounds for treating inflammation and pain. | |
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX339302B (en) | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. | |
| MX347927B (en) | Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease. | |
| MX369117B (en) | Selective ep4 receptor agonistic substance for treatment of cancer. | |
| MX2012013879A (en) | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases. | |
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 MAR 2018 BY DENNEMEYER + CO. Effective date: 20170711 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2019 BY JING LEI Effective date: 20180309 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2020 BY JING LEI Effective date: 20190226 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2021 BY JING LEI Effective date: 20200217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2022 BY JING LEI Effective date: 20210308 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2023 BY PAVIS PAYMENT GMBH Effective date: 20220412 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2024 BY JING LEI Effective date: 20230313 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2025 BY JING LEI Effective date: 20240313 |